Introduction
Achondroplasia is one of the most common forms of skeletal dysplasia causing disproportionate, extreme short stature in childhood as well as in adulthood.
Thus, mean adult height has been found to be 131.6 cm for males and 123.5 cm for females, respectively (1), corresponding to -6 to -7 SDS of that of the normal population. Most of the diminished height is due to shortness of the lower extremities whereas sitting height often is just below or within normal limits.
The radiological findings include to varying degrees the following traits: A large head with frontal, parietal and occipital prominence; a narrow, slit shaped, foramen magnum, that is growing little from birth onwards (2) , and a small skull base; a lack of normal increase in interpeduncular distance from upper to lower lumbar spines; flat and squared iliac wings; short tubular bones and flared metaphyses; metacarpals that are of equal length; fibula length that is disproportionally increased to tibia with a further increase as the child grows; and a segmental stenosis of the spinal canal.
Life span and mental development in individuals with achondroplasia is normal. The genetic background for the disease has been revealed only recently. Achondroplasia is the consequence of a heterozygous mutation of a single nucleotide in the transmembrane region of the fibroblast growth factor receptor 3 (FGFR3) gene (3, 4) localised on chromosome 4p. The vast majority of cases of achondroplasia (> 90%) is caused by new mutations.
Inheritance is autosomal dominant with complete penetrance, and the estimated incidence is one out of 15,000-40,000 live births.
A correlation to increased paternal age has been described. included in the study only if the age at start of treatment was 4-10 years (girls) and 4-12 years (boys). Only prepubertal children were considered for the study. Results on treatment were considered in this report only as long as the children are prepubertal. Puberty was defined as the attainment of stadium B2 (girls) and testis size 4 ml (boys).
The patients were, after stratification for age (strata 4.00-7.99 years of age/8.00 years of age and older), randomly allocated to one of the doses 0.1 or 0.2 IU/kg per day. The diagnosis of achondroplasia was established from radiological and clinical (including auxological) criteria. All radiographs were read by the same investigator (OE). Confirmation of the achondroplasiaspecific mutation of the study subjects with molecular genetic methods is presently in progress and is positive for all individuals tested so far.
Methods

Auxological measurements
Standing height, sitting height, and armspan were measured every third month during the study. An X-ray of left hand-wrist was taken at start of treatment and then yearly during treatment.
Total height was expressed in SDS according to Karlberg (11) , and growth velocity was expressed in SDS according to Tanner (12) . The ratio of sitting height to standing height and armspan were expressed in SDS according to Gerver (13) . Serum insulin-like growth factor I (IGF-1) levels were expressed as SDS according to Juul et al. (14) . Bone age was expressed in SDS according to Greulich and Pyle, and the ratio between change in bone age and chronological age was calculated.
Biochemical measurements
Before start of treatment and every 3-6 months during therapy s-IGF-I was measured. The IGF-I method was a polyclonal RIA performed after acid-ethanol extraction and using Table  1 Pretreatment data for prepubertal children with achondopla sia Table  2 spectively, which is significantly more for the higher dose.
For the patients who completed 24 mon of treatment there was a clear dose-response relationship which was also shown by the significant differences in growth velocity as well as in the standardised height between the dose groups . Standardised growth velocity during treatment was significantly higher than the pre-treatment value for both dose groups , also when considering first and second treatment year separately (0.1 IU/kg: first year p<0.0001; second year Table 2 .
A comparison of the data in Table 2 which includes only the patients who completed the 24 mon of treatment with the data of all patients including the drop-out patients, reveals that there are only small, differences in mean values of height or growth velocity. It can therefore be concluded that the drop-out patients were neither shorter nor taller or had different growth velocities than the patients who completed the 24 mon period.
Discussion
The present investigation showed that two years of growth hormone treatment in achondroplasia significantly increased growth velocity and height in a dose-response relationship without worsening body proproportions and without causing pathologically increased circulating s- 
